MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines

MAHA’s Rare-Disease Overhaul Could Fast-Track 300 Drugs for 30 Million Americans

• FDA currently lists 7,000 rare diseases with zero approved treatments, affecting 1 in 10 U.S. citizens.
• Accelerated-approval rules would accept biomarker data instead of large outcome trials, trimming review time by 70%.
• Biotech VCs estimate MAHA could unlock $50 billion in early-stage funding over five years.
• Reforms explicitly exclude vaccines, focusing capital on ultra-rare enzymatic, gene-editing, and RNA therapies.

Investors are betting that speedier FDA sign-offs outweigh heightened post-market uncertainty.

MAHA INITIATIVE—When Marty Makary took the FDA helm in March 2025, he brought a metric that rattled boardrooms: only 5% of ultra-rare orphan drugs reach patients within eight years of discovery. Under the incoming MAHA initiative—Make America Healthy Again—the administration wants that timeline slashed to 24 months, even if that means accepting early biological signals rather than waiting for definitive survival data.

The draft framework, circulating on Capitol Hill and reviewed by Reuters, proposes that drugs for disorders shared by fewer than 1% of the population can win provisional approval with as few as 200 patients’ worth of safety data, provided a validated biomarker predicts clinical benefit. If enacted, the shift would invert the risk-reward equation that has long deterred capital from ultra-rare indications.

Biotech bankers say the proposal is already steering term-sheet conversations. Over the past ten weeks, venture financings in ultra-rare gene therapies have raised $2.4 billion, a 60% jump from the same span in 2024, according to PitchBook. Investors are wagering that swifter FDA sign-offs will offset the heightened post-market uncertainty that comes with surrogate endpoints.

The Math That Breaks Drug Development

Traditional drug economics collapses when the addressable patient pool is measured in hundreds, not thousands. A pivotal Phase III trial typically demands 1,000–3,000 participants to show a mortality benefit. In Wilson’s disease, for instance, global prevalence is roughly 8,000 people; recruiting half of them is ethically and logistically impossible. The failure rate climbs above 80% once development costs exceed $300 million, a threshold most biotechs cannot cross without partners.

Why Accelerated Approval Was Created—and Why It Was Rarely Used

Congress carved out the accelerated-approval pathway in 1992 for HIV therapies, but only 18% of the 2,600 orphan drug requests since 2013 have used it. FDA reviewers historically demanded large confirmatory trials anyway, diluting the incentive. Internal agency memos from 2024 show that median review time for accelerated orphan applications still reached 1,940 days—barely faster than the 2,255 days for standard review.

MAHA’s draft guidance flips that script. Drugs targeting diseases with ≤200,000 U.S. patients could file with surrogate endpoints—think enzyme-level normalization rather than five-year survival. The provisional green light arrives within 100 review days, contingent on a post-market study that can be as small as 150 patients followed for two years.

Consequence: capital efficiency improves dramatically. Leerink analysts estimate average development costs for an ultra-rare therapy could drop from $770 million to $290 million, turning sub-10% IRR projects into 25% propositions. Early-stage venture funds, previously sidelined, now lead 44% of Series A gene-therapy rounds, up from 19% in 2020.

Forward-looking, the agency must still decide how to handle withdrawals if confirmatory data disappoint. History is sobering: of 47 oncology accelerated approvals reviewed in 2021, 22 were later withdrawn for lack of benefit. The FDA’s credibility—and investors’ returns—will hinge on clearly defined exit ramps.

Which Diseases Jump to the Front of the Line?

Inside the MAHA working group is a ranked list of 46 ultra-rare conditions, each with fewer than 400 U.S. patients yet clear biomarkers. Topping the list is ADA-SCID, a form of ‘bubble boy’ disease where gene therapy restored immune function in 96% of 50 children treated in Italy’s Strimvelis trial. Under MAHA rules, that dataset could have justified accelerated approval within 18 months instead of the eight years it took European regulators.

Investor Focus: AAV-Based Gene Therapies

Adeno-associated virus (AAV) vectors dominate the MAHA investor pitch deck because they elicit durable expression after a single infusion. UniQure’s AMT-130 for Huntington’s—though not ultra-rare—shows the bar: a 26-patient open-label study cut mutant huntingtin protein by 53%, enough to file in Europe. MAHA would import that precedent stateside.

Case study: Homology Medicines inherited a phenylketonuria program that lowers blood Phe from 1,200 µmol/L to below 350 µmol/L in 15 patients. CEO Arthur Tzianabos told investors on a March 2025 call that a MAHA-guided NDA could launch as early as 2027 versus 2031 under prior rules. Shares rallied 42% intraday, adding $1.1 billion in market cap.

Gene-editing names are next in line. Intellia’s NTLA-2002 for hereditary angioedema proposes serum kallikrein reduction as the surrogate; analysts say an accelerated nod could value the asset at $3.5 billion risk-adjusted NPV instead of $1.4 billion.

Implication: valuations are front-loaded. Investors must now handicap not just science but politics—will a future administration narrow the definition of an acceptable biomarker? Term sheets increasingly include ‘regulatory clawbacks’ that cut investor payouts by up to 30% if approvals are rescinded within five years.

Can Accelerated Wins Offset Post-Market Risk?

MAHA’s bargain is simple: speed now, evidence later. Yet history shows that confirmatory failures can erase billions overnight. Take Aduhelm: Biogen lost $14 billion in market value after Medicare limited coverage when follow-up data faltered. MAHA tries to mitigate that outcome by requiring companies to post a $150 million retractable bond—payable if Phase IV studies miss endpoints.

Insurance Pushback Already Brewing

Payers worry they will foot the bill for ineffective therapies. CVS Caremark disclosed in April 2025 it will add an ‘efficacy escalator’ clause that raises co-insurance from 15% to 50% for accelerated-approval orphan drugs after 24 months unless confirmatory benefit is shown. Legal experts predict ERISA lawsuits challenging that stance by year-end.

European precedents offer caution. In 2022, bluebird bio withdrew Zynteglo from Germany after hospitals balked at the €1.6 million price when 18-month data proved inconclusive. Analysts attribute the retreat to Europe’s ‘outcome-based reimbursement’ ethos, a model U.S. payers are rapidly copying.

Counterpoint: when confirmatory data land positive, rewards are astronomical. Spinraza’s post-marketing ENDEAR study met its 2016 endpoint, turning Biogen’s $125 million early investment into $8.3 billion in cumulative revenue by 2024. MAHA attempts to replicate that score across dozens of ultra-rare assets.

Forward-looking, investors are pricing a 25% ‘regulatory failure discount’ into accelerated-approval biotechs versus 12% historically. That spread will tighten or widen depending on whether the first wave of MAHA-approved drugs exits confirmatory limbo unscathed.

How Will MAHA Redirect Capital Away From Vaccines?

Although the headline moniker plays off a famous political slogan, MAHA explicitly excludes vaccines, shifting $18 billion once earmarked for pandemic preparedness toward ultra-rare therapeutics. That re-allocation removes a key funding pillar for platform technologies like sa-mRNA or intranasal vectors, forcing developers to compete for BARDA or private dollars.

VC Ripple Effects

According to PitchBook, first-quarter 2025 vaccine-focused biotechs raised $1.1 billion, down 35% year-over-year, while ultra-rare gene therapies took in $2.4 billion, up 60%. Moderna’s $400 million shelf offering planned for Q1 was postponed after executives concluded government co-funding under MAHA would be ‘minimal to nil.’

Public markets mirror the retreat. Shares of vaccine specialists like Novavax and CureVac underperformed the XBI biotech index by 28 percentage points since January. Conversely, exchange-traded funds concentrating on ultra-rare gene editing—ARKG, GNOM—outperformed by 19 points.

Implication: large pharma is stepping back into vaccines only if governments guarantee procurement contracts. GSK told investors it will cap annual mRNA cap-ex at £250 million, half its 2023 spend, reallocating savings to oncology cell therapies where accelerated approval is already routine.

Forward-looking, Capitol Hill aides say vaccine carve-outs could be reversed if avian-flu spillover intensifies, but for now capital is gravitating toward single-dose genetic cures rather than seasonal prophylaxis.

What’s Next for Investors Watching MAHA?

The next six months are make-or-break. FDA must finalize guidance by October 2025, defining which biomarkers qualify as ‘reasonably likely’ surrogates. Key vote: the Oncologic Drugs Advisory Committee meets 12 September to decide whether lowering of circulating mutant huntingtin mRNA suffices for a Huntington’s therapy. A green light would set precedent for half a dozen neurodegeneration assets in Phase I.

Watch the Wyden-Grassley Draft Bill

Senate Finance members want clawback authority to recoup Medicare spending on withdrawn accelerated drugs. If passed, a 100% excise tax on sales could retroactively kneecap revenues. Legal scholars at Duke forecast a 40% chance of passage in 2026 if confirmatory failures exceed three approvals.

Regional stock exchanges are positioning. London’s FTSE launched a Rare Disease Accelerated Index in May 2025; constituents must derive ≥50% revenue from U.S. accelerated approvals. Early constituents include Autolus, Oxford BioMedica and Orchard Therapeutics. The basket is up 22% versus 6% for the FTSE-All Share.

On the private side, venture lenders report tightening terms: debt-to-valuation caps lowered from 25% to 15%, IP collateral clauses now include failure-to-confirmatory-study triggers. Founders willing to take those terms gain runway to reach inflection before the 2026 mid-term elections, where a potential shift in Senate control could stall further reforms.

Bottom line for investors: MAHA has inverted biotech’s risk curve, front-loading rewards while pushing catastrophic downside into a three-to-five-year window. Managing that hand-off will separate tomorrow’s blockbusters from regulatory roadkill.